Abbott Laboratories Total Liabilities
Abbott Laboratories total liabilities. Based on the latest financial reports, Abbott Laboratories (ABT) has total liabilities worth $32.92 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Abbott Laboratories asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Abbott Laboratories (1985–2024)
Total liabilities of Abbott Laboratories from 1985 to 2024. This chart illustrates how Abbott Laboratories's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Abbott Laboratories to see how much of total assets are deployed in long-term investments.
Abbott Laboratories Competitors by Total Liabilities
The table below lists competitors of Abbott Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verizon Communications Inc
SA:VERZ34
|
Brazil | R$304.99 Billion |
|
Mitsubishi UFJ Financial Group Inc ADR
NYSE:MUFG
|
USA | $407.03 Trillion |
|
Reliance Industries Limited
NSE:RELIANCE
|
India | Rs-10.86 Trillion |
|
SHELL PLC WI ADR/2
F:L3H
|
Germany | €198.73 Billion |
|
Verizon Communications Inc
NYSE:VZ
|
USA | $304.99 Billion |
|
McDonald’s Corporation
NYSE:MCD
|
USA | $61.32 Billion |
|
PepsiCo Inc
NASDAQ:PEP
|
USA | $89.92 Billion |
|
MediaTek Inc
TW:2454
|
Taiwan | NT$340.33 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Abbott Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Abbott Laboratories.
Liquidity & Leverage Metrics
Abbott Laboratories Total Liabilities Ratios Explained
Abbott Laboratories total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.52 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abbott Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abbott Laboratories (1985–2024)
The table below shows the annual total liabilities of Abbott Laboratories from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.51 Billion | -2.54% |
| 2023-12-31 | $34.39 Billion | -8.38% |
| 2022-12-31 | $37.53 Billion | -4.18% |
| 2021-12-31 | $39.17 Billion | -0.94% |
| 2020-12-31 | $39.55 Billion | +8.09% |
| 2019-12-31 | $36.59 Billion | +0.37% |
| 2018-12-31 | $36.45 Billion | -19.27% |
| 2017-12-31 | $45.15 Billion | +41.33% |
| 2016-12-31 | $31.95 Billion | +60.38% |
| 2015-12-31 | $19.92 Billion | +1.45% |
| 2014-12-31 | $19.64 Billion | +11.03% |
| 2013-12-31 | $17.69 Billion | -56.25% |
| 2012-12-31 | $40.42 Billion | +13.07% |
| 2011-12-31 | $35.75 Billion | -3.34% |
| 2010-12-31 | $36.99 Billion | +25.30% |
| 2009-12-31 | $29.52 Billion | +18.36% |
| 2008-12-31 | $24.94 Billion | +13.70% |
| 2007-12-31 | $21.94 Billion | -0.85% |
| 2006-12-31 | $22.12 Billion | +50.24% |
| 2005-12-31 | $14.73 Billion | +1.97% |
| 2004-12-31 | $14.44 Billion | +5.85% |
| 2003-12-31 | $13.64 Billion | +0.36% |
| 2002-12-31 | $13.59 Billion | -4.51% |
| 2001-12-31 | $14.24 Billion | +112.10% |
| 2000-12-31 | $6.71 Billion | -4.70% |
| 1999-12-31 | $7.04 Billion | -6.12% |
| 1998-12-31 | $7.50 Billion | +6.23% |
| 1997-12-31 | $7.06 Billion | +12.01% |
| 1996-12-31 | $6.31 Billion | +25.71% |
| 1995-12-31 | $5.02 Billion | +12.10% |
| 1994-12-31 | $4.47 Billion | +11.48% |
| 1993-12-31 | $4.01 Billion | +11.69% |
| 1992-12-31 | $3.59 Billion | +17.73% |
| 1991-12-31 | $3.05 Billion | +11.82% |
| 1990-12-31 | $2.73 Billion | +28.44% |
| 1989-12-31 | $2.13 Billion | -9.97% |
| 1988-12-31 | $2.36 Billion | +2.98% |
| 1987-12-31 | $2.29 Billion | +9.85% |
| 1986-12-31 | $2.09 Billion | +30.61% |
| 1985-12-31 | $1.60 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more